Cardurion Pharmaceuticals

18 articles about Cardurion Pharmaceuticals

• Cardurion Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  1/5/2024

  Cardurion Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

• Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023

  11/7/2023

  Cardurion Pharmaceuticals, Inc. today announced that the Company will present preclinical data on its Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor program at the American Heart Association’s (AHA) Scientific Sessions 2023.

• Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair

  10/4/2023

  Cardurion Pharmaceuticals, Inc. today announced the appointment of Emma Reeve as an independent board director and audit chair.

• Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel

  4/19/2023

  Cardurion Pharmaceuticals, Inc. today announced the appointment of Stephen Migausky as Senior Vice President and General Counsel.

• Cardurion Pharmaceuticals Strengthens Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer

  1/19/2023

  Cardurion Pharmaceuticals Strengthens Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer.

• Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure

  7/19/2022

  Cardurion Pharmaceuticals, Inc. today announced it has opened multiple sites and commenced dosing patients in a Phase 2 clinical trial of CRD-740, a phosphodiesterase-9 (“PDE9”) inhibitor for the treatment of heart failure.

• Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer

  2/16/2022

  Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer.

• Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital

  10/27/2021

  Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital

• Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer

  7/8/2020

  Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Chris Morabito, M.D., as chief medical officer (CMO). Dr. Morabito joins Cardur

• 

  BioSpace Movers & Shakers, April 17

  4/17/2020

  Pharma and life sciences companies boost their executive ranks and boards with this week's Movers & Shakers.

• Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer

  4/15/2020

  Cardurion Pharmaceuticals, Inc. today announced the appointment of Peter S. Lawrence as president and chief executive officer. Mr. Lawrence joins Cardurion after serving for almost 14 years as president and chief operating offi

• Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors

  11/20/2019

  Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced that it has consummated a private investment from Polaris Partners, a leading healthcare investment firm with a long history of partnering with entrepreneurs in biotechnology

• Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure

  11/12/2018

  ​CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models

• Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure

  9/20/2018

  Cardurion Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733

• Cardurion Pharmaceuticals Appoints Rebecca Frey as Chief Operating Officer

  7/24/2018

  Cardurion Pharmaceuticals, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.

• Cardurion Pharmaceuticals Announces Formation of Scientific and Clinical Advisory Board

  6/26/2018

  Cardurion Pharmaceuticals is pleased to share the members of its Scientific and Clinical Advisory Boards.

• Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas

  4/16/2018

  Company expanding pipeline of novel treatments for cardiovascular disease

• Takeda And Cardurion Pharma Launch Cardiovascular Development Partnership

  8/2/2017